Genetic Variations in the Mycophenolate Mofetil Target Enzyme Are Associated with Acute GVHD Riskafter Related and Unrelated Hematopoietic CellTransplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 2, 2012, Pages 273-279

  Cao, Weijie ^a,c   Xiao, Haowen ^a,b   Lai, Xiaoyu ^a   Luo, Yi ^a   Shi, Jimin ^a   Tan, Yamin ^a   Zheng, Weiyan ^a   He, Jingsong ^a   Xie, Wanzhuo ^a   Li, Li ^a   Ye, Xiujin ^a   Yu, Xiaohong ^a   Lin, Maofang ^a   Cai, Zhen ^a   Huang, He ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Department of Haematology   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

AGVHD; Hematopoietic stem cell transplantation; IMPDH1; Polymorphism

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; INOSINATE DEHYDROGENASE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DNA FLANKING REGION; DRUG TARGETING; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HLA TYPING; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; ORGAN DONOR; OUTCOME ASSESSMENT; PROMOTER REGION; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SCHOOL CHILD; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; EXONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMP DEHYDROGENASE; INTRONS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855614892     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.06.014     Document Type: Article

References (37)

1. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
2. Sun Y., Tawara I., Toubai T., Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 2007, 150:197-214.
3. Rocha V., Porcher R., Fernandes J.F., et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009, 23:545-556.
4. Dickinson A.M., Holler E. Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol 2008, 21:149-164.
5. Penack O., Holler E., van den Brink M.R. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 2010, 115:1865-1872.
6. Ball L.M., Egeler R.M. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant 2008, 41(Suppl 2):S58-S64.
7. Espinoza J.L., Takami A., Onizuka M., et al. NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica 2009, 94:1427-1434.
8. Shu Q., Nair V. Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery. Med Res Rev 2008, 28:219-232.
9. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47:85-118.
10. Glander P., Braun K.P., Hambach P., et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001, 34:543-549.
11. Glander P., Hambach P., Braun K.P., et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004, 4:2045-2051.
12. Gensburger O., Van Schaik R.H., Picard N., et al. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics 2010, 20:537-543.
13. Sombogaard F., van Schaik R.H., Mathot R.A., et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics 2009, 19:626-634.
14. Wang J., Yang J.W., Zeevi A., et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008, 83:711-717.
15. Wang J., Zeevi A., Webber S., et al. A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007, 17:283-290.
16. Vogelsang G.B., Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001, 27:1255-1262.
17. Neumann F., Graef T., Tapprich C., et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005, 35:1089-1093.
18. Ostronoff F., Ostronoff M., Souto-Maior A.P., et al. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant 2009, 23:33-38.
19. Pinana J.L., Valcarcel D., Fernandez-Aviles F., et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010, 45:1449-1456.
20. Lai Y., Ma J., Schwarzenberger P., et al. Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis. Bone Marrow Transplant 2009, 43:61-67.
21. He Huang, Maofang Lin, Haitao Meng, et al. Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation. Zhonghua Xue Ye Xue Za Zhi 2001, 22:76-78.
22. Huang H., Zheng W., Lin M., Fu J., Zhang R. Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model. Zhonghua Xue Ye Xue Za Zhi 2002, 23:191-193.
23. Zhu X., Lai X., Luo Y., Shi J., Tan Y., Huang H. Combination of mycophenolate mofetil with cyclosporine A and methotrexate as GVHD prophylaxis in unrelated donor allogeneic hematopoietic stem cell transplantation. Blood 2010, 116:1280.
24. Yan H., Yuan W., Velculescu V.E., Vogelstein B., Kinzler K.W. Allelic variation in human gene expression. Science 2002, 297:1143.
25. Donn R., Payne D., Ray D. Glucocorticoid receptor gene polymorphisms and susceptibility to rheumatoid arthritis. Clin Endocrinol (Oxf) 2007, 67:342-345.
26. Sistonen J., Fuselli S., Levo A., Sajantila A. CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 2005, 51:1291-1295.
27. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
28. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
29. Ferrara J.L., Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006, 43:3-10.
30. Xiao H., Cao W., Lai X., et al. Immunosuppressive cytokine gene polymorphisms and outcome after related and unrelated hematopoietic cell transplantation in Chinese population. Biol Blood Marrow Transplant 2011, 17:542-549.
31. Xiao H.W., Lai X.Y., Luo Y., et al. Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population. Bone Marrow Transplant 2011, 46:400-407.
32. Murphy N., Diviney M., Szer J., et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 2006, 37:773-779.
33. Robien K., Bigler J., Yasui Y., et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2006, 12:973-980.
34. Yatscoff R.W., Aspeslet L.J., Gallant H.L. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem 1998, 44:428-432.
35. Bremer S., Vethe N.T., Rootwelt H., Bergan S. Expression of IMPDH1 is regulated in response to mycophenolate concentration. Int Immunopharmacol 2009, 9:173-180.
36. Dubsky P.C., Friedl J., Stift A., et al. Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and function of dendritic cells. Clin Chim Acta 2006, 364:139-147.
37. Sanquer S., Maison P., Tomkiewicz C., et al. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther 2008, 83:328-335.